France
-
The parent company of Caffil, the French public sector covered bond issuer, has finalised the first loan under its newly established export credit finance business. The Cover spoke to Caffil’s head of treasury and financial markets, Sami Gotrane, about the issuer’s prospective plans in the export finance business.
-
-
Pharnext, a French biopharmaceutical company specialising n treatments for neurological conditions such as Alzheimer’s disease, has successfully completed its IPO on the Alternext market of Euronext Paris.
-
Agence Française de Développement hit the sweet spot for supply-starved, yield-hungry investors on Wednesday with a 10 year euro benchmark. -
GenSight Biologics, a niche French biotechnology firm focused on treating degenerative retinal and nervous system disorders, has completed its all-primary IPO on Euronext Paris, raising €46m to help bring its flagship drug GS010 to market in Europe and the US.
-
Agence Française de Développement looked set to become only the second borrower to emerge with a euro benchmark since the UK’s Brexit vote after announcing plans for a new 10 year on Tuesday.
-
Foncia, the French residential real estate company, on Tuesday began marketing its €1bn LBO loan into an "issuer friendly" market, according to one investor.
-
Tikehau Capital, the French asset manager that specialises in private debt, has raised €510m of new share capital, including from Temasek and the Peugeot family, as it targets opportunities outside Europe.
-
Covered bond secondary market volumes saw a small improvement on Thursday, but with limited supply and continued central bank buying, the market is set to become more technically squeezed over summer.
-
Covered bonds saw a relative improvement in flows on Thursday, but with a limited supply outlook and continued central bank buying, a technical squeeze had begun to take hold. CIF Euromortgage performed well after regaining preferential regulatory treatment.
-
The European investment grade corporate bond market has been ticking along like a metronome this week, printing a steady deal a day. And encouragingly, big deals have returned.
-
GenSight Biologics, a French biotechnology firm specialising in treatments for degenerative retinal diseases and central nervous system disorders, has opened the books for its all primary IPO on Euronext Paris.
